Search research articles
Contact Us
Filters
Showing results (221-230 of 251) with videos related to
Page
of 26
Sort By:
Pediatric Blood & Cancer
|
January 24, 2017
Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study)
Brice Fresneau, A Hackshaw, D S Hawkins, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 18, 2025
Pandemic driven preoperative moderate hypofractionated radiotherapy for soft tissue sarcomas
G F Foppele, M Fiocco, J F Ubbels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2021
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)<sup>☆</sup>
P G Casali, A Le Cesne, A P Velasco, et al.
Scientific Reports
|
October 12, 2019
Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor
F G M Verspoor, M J L Mastboom, G Hannink, et al.
British Journal of Cancer
|
November 11, 2010
Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients
M H Nieuwenhuis, E M Mathus-Vliegen, C G Baeten, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 2022
Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study
S L Groenland, R A G van Eerden, K Westerdijk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 8, 2017
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'
P Schöffski, A Wozniak, B Kasper, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 18, 2022
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
J M van Berge Henegouwen, M Jebbink, L R Hoes, et al.
Breast Cancer Research and Treatment
|
February 12, 2022
Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses
E Palassini, O Mir, G Grignani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 2019
Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients
S B van Waalwijk van Doorn-Khosrovani, A Pisters-van Roy, L van Saase, et al.
Page
of 26
Search research articles
Search
Showing results (221-230 of 251) with videos related to
Sort By:
Page
of 26
Pediatric Blood & Cancer
|
January 24, 2017
Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study)
Brice Fresneau, A Hackshaw, D S Hawkins, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 18, 2025
Pandemic driven preoperative moderate hypofractionated radiotherapy for soft tissue sarcomas
G F Foppele, M Fiocco, J F Ubbels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2021
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)<sup>☆</sup>
P G Casali, A Le Cesne, A P Velasco, et al.
Scientific Reports
|
October 12, 2019
Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor
F G M Verspoor, M J L Mastboom, G Hannink, et al.
British Journal of Cancer
|
November 11, 2010
Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients
M H Nieuwenhuis, E M Mathus-Vliegen, C G Baeten, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 2022
Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study
S L Groenland, R A G van Eerden, K Westerdijk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 8, 2017
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'
P Schöffski, A Wozniak, B Kasper, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 18, 2022
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
J M van Berge Henegouwen, M Jebbink, L R Hoes, et al.
Breast Cancer Research and Treatment
|
February 12, 2022
Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses
E Palassini, O Mir, G Grignani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 2019
Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients
S B van Waalwijk van Doorn-Khosrovani, A Pisters-van Roy, L van Saase, et al.
Page
of 26